The White House Office of Management and Budget (OMB) has completed its review of a key regulatory step toward rescinding the Trump administration’s final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program. The final rule currently is due to take effect on July 20.
OMB finished reviewing the U.S. Health Resources and Services Administration’s (HRSA’s) recission proposal yesterday. HRSA could post its proposal, in the form of a proposed rule, for public inspection on the Federal Register website as soon as later today. There probably will be a public comment period, followed by another OMB review, before publication of a final rule later this summer rescinding the Trump-era mandate.
The White House Office of Management and Budget (OMB) has completed its review of a key regulatory step toward rescinding the Trump administration’s final rule to require health centers to provide insulin and injectable epinephrine to low-income patients at the price the centers pay for those drugs under the 340B program. The final rule currently is due to take effect on July 20.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
